Covered recipient · General Payments record
ROBERT W LEVIN
Allopathic & Osteopathic Physicians Internal Medicine Rheumatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$84,628.49
271 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $43,825.00 | 18 |
| Consulting Fee | $28,200.00 | 9 |
| Food and Beverage | $7,148.61 | 220 |
| Travel and Lodging | $5,437.19 | 23 |
| Education | $17.69 | 1 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| GENZYME CORPORATION | $24,577.90 | 37 |
| GlaxoSmithKline, LLC. | $20,441.55 | 21 |
| ABBVIE INC. | $17,352.95 | 27 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $10,112.20 | 18 |
| Novartis Pharmaceuticals Corporation | $4,891.19 | 23 |
| Janssen Biotech, Inc. | $3,578.65 | 21 |
| E.R. Squibb & Sons, L.L.C. | $1,359.73 | 5 |
| Amgen Inc. | $632.90 | 33 |
| Mallinckrodt Hospital Products Inc. | $299.60 | 18 |
| PFIZER INC. | $277.70 | 15 |
| UCB, Inc. | $266.48 | 17 |
| Lilly USA, LLC | $188.04 | 9 |
| AstraZeneca Pharmaceuticals LP | $180.80 | 5 |
| Fresenius Kabi USA, LLC | $163.27 | 8 |
| Aurinia Pharma U.S., Inc. | $108.01 | 4 |
| Kyowa Kirin, Inc. | $44.80 | 2 |
| Genentech USA, Inc. | $31.18 | 2 |
| United Therapeutics Corporation | $29.73 | 1 |
| TerSera Therapeutics LLC | $28.68 | 1 |
| SCILEX PHARMACEUTICALS INC. | $22.93 | 1 |
| Radius Health, Inc. | $19.00 | 1 |
| Fidia Pharma USA Inc. | $14.70 | 1 |
| Organon Llc | $6.50 | 1 |
Page 4 of 6; records 151–200 of 271 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ROBERT W LEVIN
NPI 1326066903 · CMS profile ID 195766
Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology
CLEARWATER, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 4 of 6; records 151–200 of 271 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1326066903?year=2024&recipient=provider&page=4#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ROBERT W LEVIN, NPI 1326066903, CMS profile ID 195766. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 6; records 151–200 of 271 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1326066903?year=2024&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). ROBERT W LEVIN, NPI 1326066903, CMS profile ID 195766. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 6; records 151–200 of 271 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1326066903?year=2024&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- ROBERT W LEVIN, NPI 1326066903, CMS profile ID 195766, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 6; records 151–200 of 271 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1326066903?year=2024&recipient=provider&page=4#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
271 matching records · $84,628.49 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 151–200 of 271.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $34.74 | 05/30/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086963598 | CMS |
| UCB, Inc. | $21.19 | 05/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143096653 | CMS |
| Amgen Inc. | $23.19 | 05/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1115867475 | CMS |
| GlaxoSmithKline, LLC. | $28.36 | 05/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116584801 | CMS |
| Janssen Biotech, Inc. | $22.65 | 05/24/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078405793 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $2,610.00 | 05/22/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117963776 | CMS |
| Lilly USA, LLC | $9.27 | 05/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135397565 | CMS |
| AstraZeneca Pharmaceuticals LP | $24.30 | 05/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104332364 | CMS |
| Amgen Inc. | $4.63 | 05/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1115867534 | CMS |
| PFIZER INC. | $16.26 | 05/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131821638 | CMS |
| PFIZER INC. | $2.18 | 05/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131802851 | CMS |
| Janssen Biotech, Inc. | $29.00 | 05/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078405783 | CMS |
| GENZYME CORPORATION | $37.15 | 05/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139630335 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $745.48 | 05/13/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117963772 | CMS |
| ABBVIE INC. | $46.02 | 05/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104166002 | CMS |
| Amgen Inc. | $51.42 | 05/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1115867465 | CMS |
| GENZYME CORPORATION | $131.90 | 05/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139630327 | CMS |
| GlaxoSmithKline, LLC. | $41.93 | 05/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116408373 | CMS |
| Janssen Biotech, Inc. | $2,160.00 | 05/09/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078406059 | CMS |
| Janssen Biotech, Inc. | $27.56 | 05/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078406508 | CMS |
| GlaxoSmithKline, LLC. | $10,296.00 | 05/08/2024 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1155880103 | CMS |
| Janssen Biotech, Inc. | $40.13 | 05/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078406073 | CMS |
| Janssen Biotech, Inc. | $127.46 | 05/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078406249 | CMS |
| Janssen Biotech, Inc. | $31.19 | 05/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078406607 | CMS |
| Novartis Pharmaceuticals Corporation | $2,875.00 | 05/08/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086963584 | CMS |
| Novartis Pharmaceuticals Corporation | $144.90 | 05/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086963622 | CMS |
| Genentech USA, Inc. | $17.32 | 05/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133098755 | CMS |
| Janssen Biotech, Inc. | $323.68 | 05/07/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078406036 | CMS |
| Novartis Pharmaceuticals Corporation | $30.14 | 05/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086963594 | CMS |
| PFIZER INC. | $12.07 | 05/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131824172 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $35.00 | 05/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117963762 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $140.00 | 05/06/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117963770 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $2,320.00 | 05/06/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117963774 | CMS |
| Fresenius Kabi USA, LLC | $14.90 | 05/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1146955544 | CMS |
| Mallinckrodt Hospital Products Inc. | $22.47 | 05/03/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145098921 | CMS |
| GENZYME CORPORATION | $4,191.00 | 05/02/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139630367 | CMS |
| GENZYME CORPORATION | $924.80 | 05/02/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139630369 | CMS |
| Mallinckrodt Hospital Products Inc. | $3.07 | 05/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145098916 | CMS |
| Amgen Inc. | $24.93 | 05/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1115867600 | CMS |
| AstraZeneca Pharmaceuticals LP | $92.75 | 05/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105774580 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $90.22 | 05/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117963764 | CMS |
| Lilly USA, LLC | $19.68 | 04/30/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135373982 | CMS |
| Aurinia Pharma U.S., Inc. | $18.89 | 04/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150686141 | CMS |
| GlaxoSmithKline, LLC. | $219.35 | 04/26/2024 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1155878143 | CMS |
| GlaxoSmithKline, LLC. | $70.91 | 04/26/2024 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1155878367 | CMS |
| GlaxoSmithKline, LLC. | $44.80 | 04/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1155882123 | CMS |
| Janssen Biotech, Inc. | $3.78 | 04/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078405944 | CMS |
| GlaxoSmithKline, LLC. | $145.01 | 04/21/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116442489 | CMS |
| GlaxoSmithKline, LLC. | $145.01 | 04/21/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116506943 | CMS |
| PFIZER INC. | $27.06 | 04/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131820924 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,711,512.66 | 170 |
| PY2024 | Principal investigator | $1,193,584.92 | 76 |
| PY2023 | Recipient | $1,231.34 | 8 |
| PY2023 | Principal investigator | $1,901,843.40 | 118 |
| PY2022 | Recipient | $283.50 | 1 |
| PY2022 | Principal investigator | $1,735,645.23 | 277 |
| PY2021 | Recipient | $1,747.15 | 2 |
| PY2021 | Principal investigator | $1,442,306.37 | 210 |
| PY2020 | Recipient | $6,500.60 | 5 |
| PY2020 | Principal investigator | $1,189,717.94 | 200 |
| PY2019 | Recipient | $692.31 | 2 |
| PY2019 | Principal investigator | $1,457,403.01 | 189 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
170 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $250.92 | 12/31/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | A Phase 3b/4 Randomized, Double-Blind, Double Dummy, Active Comparator-Controlled Study, Comparing the Efficacy and Safety of Upadacitinib Versus Adalimumab in Subjects with Moderate to Severe Rheumatoid Arthritis on a Stable Background of MTX and who had an Inadequate Response or Intolerance to a Single TNF Inhibitor (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202533483 |
| Principal investigator 1 | ARGENX US, INC. | $2,500.00 | 12/24/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148552 |
| Principal investigator 1 | ARGENX US, INC. | $2,500.00 | 12/24/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148555 |
| Principal investigator 1 | ARGENX US, INC. | $447.10 | 12/24/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148559 |
| Principal investigator 1 | ARGENX US, INC. | $4,560.00 | 12/24/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148563 |
| Principal investigator 1 | ARGENX US, INC. | $2,000.00 | 12/24/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148575 |
| Principal investigator 1 | ARGENX US, INC. | $2,000.00 | 12/24/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148577 |
| Principal investigator 1 | ARGENX US, INC. | $750.00 | 12/24/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148589 |
| Principal investigator 1 | ARGENX US, INC. | $1,500.00 | 12/24/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148597 |
| Principal investigator 1 | ARGENX US, INC. | $1,500.00 | 12/24/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148601 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,325.00 | 12/22/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA I | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? | No dispute reported | 06/30/2026 | 1175394297 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $5,399.32 | 12/17/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | INSPIRE LTE study | No dispute reported | 06/30/2026 | 1246431094 |
| Principal investigator 1 | ABBVIE INC. | $2,327.50 | 12/04/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202526532 |
| Principal investigator 1 | ABBVIE INC. | $1,542.45 | 12/04/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate | No dispute reported | 06/30/2026 | 1202526534 |
| Principal investigator 1 | ABBVIE INC. | $6,375.00 | 12/04/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202528640 |
| Principal investigator 1 | ABBVIE INC. | $842.50 | 12/04/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202528642 |
| Principal investigator 1 | Janssen Research & Development, LLC | $35,250.00 | 11/27/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA I | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? | No dispute reported | 06/30/2026 | 1175394264 |
| Principal investigator 1 | ARGENX US, INC. | $1,928.00 | 11/20/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148545 |
| Principal investigator 1 | ARGENX US, INC. | $726.00 | 11/20/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148549 |
| Principal investigator 1 | ARGENX US, INC. | $5,895.00 | 11/20/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148571 |
| Principal investigator 1 | ARGENX US, INC. | $5,835.00 | 11/20/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148592 |
| Principal investigator 1 | ARGENX US, INC. | $1,881.00 | 11/20/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148608 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $3,424.27 | 11/19/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | INSPIRE LTE study | No dispute reported | 06/30/2026 | 1246431098 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,995.68 | 11/19/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLOR | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223288591 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $87.21 | 11/13/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | INSPIRE LTE study | No dispute reported | 06/30/2026 | 1246431110 |
| Principal investigator 1 | ABBVIE INC. | $4,807.50 | 11/04/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202520855 |
| Principal investigator 1 | ABBVIE INC. | $2,462.50 | 11/04/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202520889 |
| Principal investigator 1 | ABBVIE INC. | $1,542.45 | 11/04/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate | No dispute reported | 06/30/2026 | 1202520891 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,900.00 | 10/27/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA I | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? | No dispute reported | 06/30/2026 | 1175394291 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $6,855.98 | 10/15/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLOR | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223287011 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,775.00 | 10/10/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA I | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? | No dispute reported | 06/30/2026 | 1175394233 |
| Principal investigator 1 | ABBVIE INC. | $1,880.45 | 10/09/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate | No dispute reported | 06/30/2026 | 1202514387 |
| Principal investigator 1 | ABBVIE INC. | $1,345.00 | 10/02/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202513063 |
| Principal investigator 1 | ARGENX US, INC. | $108.00 | 10/02/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148522 |
| Principal investigator 1 | ARGENX US, INC. | $275.00 | 10/02/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148525 |
| Principal investigator 1 | ARGENX US, INC. | $101.00 | 10/02/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148528 |
| Principal investigator 1 | ARGENX US, INC. | $3,470.00 | 10/02/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148531 |
| Principal investigator 1 | ARGENX US, INC. | $726.00 | 10/02/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148535 |
| Principal investigator 1 | ARGENX US, INC. | $726.00 | 10/02/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148538 |
| Principal investigator 1 | ARGENX US, INC. | $1,881.00 | 10/02/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148542 |
| Principal investigator 1 | ARGENX US, INC. | $405.00 | 10/02/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148567 |
| Principal investigator 1 | ARGENX US, INC. | $4,560.00 | 10/02/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148581 |
| Principal investigator 1 | ARGENX US, INC. | $4,560.00 | 10/02/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148586 |
| Principal investigator 1 | ARGENX US, INC. | $371.00 | 10/02/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148604 |
| Principal investigator 1 | ARGENX US, INC. | $303.00 | 10/02/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148611 |
| Principal investigator 1 | ARGENX US, INC. | $169.00 | 10/02/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148616 |
| Principal investigator 1 | ARGENX US, INC. | $81.00 | 10/02/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148620 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,650.00 | 10/02/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA I | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? | No dispute reported | 06/30/2026 | 1175394102 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,550.00 | 09/29/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA I NC | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? | No dispute reported | 06/30/2026 | 1175394165 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,900.00 | 09/22/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA I NC | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? | No dispute reported | 06/30/2026 | 1175394191 |
| Principal investigator 1 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $91,632.95 | 09/05/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF SIBEPRENLIMAB ADMINISTERED SUBCUTANEOUSLY IN SUBJECTS WITH ACTIVE PRIMARY SJGRENS SYNDROME (PSS) | No dispute reported | 06/30/2026 | 1225336109 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,625.00 | 08/28/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA I NC | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? | No dispute reported | 06/30/2026 | 1175394269 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $4,000.00 | 08/25/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | No dispute reported | 06/30/2026 | 1246431100 |
| Principal investigator 1 | ARGENX US, INC. | $1,806.00 | 08/13/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148844 |
| Principal investigator 1 | ARGENX US, INC. | $1,921.00 | 08/13/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148848 |
| Principal investigator 1 | ARGENX US, INC. | $726.00 | 08/13/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148852 |
| Principal investigator 1 | ARGENX US, INC. | $4,560.00 | 08/13/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148855 |
| Principal investigator 1 | ARGENX US, INC. | $6,402.00 | 08/13/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148859 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,750.00 | 08/11/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA I NC | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? | No dispute reported | 06/30/2026 | 1175394222 |
| Principal investigator 1 | IDORSIA PHARMACEUTICALS US INC | $3,000.00 | 08/07/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy | No dispute reported | 06/30/2026 | 1243532279 |
| Principal investigator 1 | IDORSIA PHARMACEUTICALS US INC | $10,000.00 | 08/07/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy | No dispute reported | 06/30/2026 | 1243532285 |
| Principal investigator 1 | IDORSIA PHARMACEUTICALS US INC | $1,000.00 | 08/07/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy | No dispute reported | 06/30/2026 | 1243532292 |
| Principal investigator 1 | IDORSIA PHARMACEUTICALS US INC | $2,000.00 | 08/07/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy | No dispute reported | 06/30/2026 | 1243532297 |
| Principal investigator 1 | ABBVIE INC. | $6,169.80 | 08/05/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate | No dispute reported | 06/30/2026 | 1202501172 |
| Principal investigator 1 | ABBVIE INC. | $10,000.00 | 08/05/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202501174 |
| Principal investigator 1 | ABBVIE INC. | $4,699.75 | 08/05/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202501944 |
| Principal investigator 1 | ARGENX US, INC. | $53.00 | 08/04/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148874 |
| Principal investigator 1 | ARGENX US, INC. | $95.50 | 08/04/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148878 |
| Principal investigator 1 | ARGENX US, INC. | $1.40 | 08/04/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148882 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,855.25 | 08/01/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223283433 |
| Principal investigator 1 | ABBVIE INC. | $5,000.00 | 07/31/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202500594 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,000.00 | 07/30/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA I NC | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? | No dispute reported | 06/30/2026 | 1175394120 |
| Principal investigator 1 | Amgen Inc. | $4,959.85 | 07/28/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC- CLEARWATER | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity | No dispute reported | 06/30/2026 | 1246640333 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,350.00 | 07/28/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA I NC | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? | No dispute reported | 06/30/2026 | 1175394257 |
| Principal investigator 1 | ARGENX US, INC. | $5,895.00 | 07/25/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148841 |
| Principal investigator 1 | Amgen Inc. | $137,827.25 | 07/07/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity | No dispute reported | 06/30/2026 | 1246640343 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,750.00 | 07/07/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA I NC | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | No dispute reported | 06/30/2026 | 1175394279 |
| Principal investigator 1 | ABBVIE INC. | $7,857.25 | 07/02/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202494413 |
| Principal investigator 1 | ARGENX US, INC. | $37.60 | 07/01/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148862 |
| Principal investigator 1 | ARGENX US, INC. | $79.50 | 07/01/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148867 |
| Principal investigator 1 | ARGENX US, INC. | $1.40 | 07/01/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148871 |
| Principal investigator 1 | ARGENX US, INC. | $191.00 | 07/01/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148885 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,500.00 | 07/01/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223281988 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,050.00 | 06/30/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA I NC | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? | No dispute reported | 06/30/2026 | 1175394203 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $76.54 | 06/27/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | INSPIRE LTE study | No dispute reported | 06/30/2026 | 1246431108 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $4,257.90 | 06/25/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | INSPIRE LTE study | No dispute reported | 06/30/2026 | 1246431096 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,855.25 | 06/25/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223281864 |
| Principal investigator 1 | ARGENX US, INC. | $3,296.50 | 06/23/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148501 |
| Principal investigator 1 | ABBVIE INC. | $1,680.00 | 06/20/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202492555 |
| Principal investigator 1 | UCB SA | $399.33 | 06/19/2025 | Non-covered Recipient Entity Clinical Research Of West Florida | A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. | No dispute reported | 06/30/2026 | 1246659643 |
| Principal investigator 1 | ARGENX US, INC. | $75.20 | 06/18/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148624 |
| Principal investigator 1 | ARGENX US, INC. | $1.75 | 06/18/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148628 |
| Principal investigator 1 | ARGENX US, INC. | $6.30 | 06/18/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148632 |
| Principal investigator 1 | ARGENX US, INC. | $159.00 | 06/18/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148636 |
| Principal investigator 1 | ARGENX US, INC. | $214.80 | 06/18/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148640 |
| Principal investigator 1 | ARGENX US, INC. | $573.00 | 06/18/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148645 |
| Principal investigator 1 | ARGENX US, INC. | $143.25 | 06/18/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148650 |
| Principal investigator 1 | ARGENX US, INC. | $668.50 | 06/18/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148653 |
| Principal investigator 1 | ARGENX US, INC. | $286.50 | 06/18/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148657 |
| Principal investigator 1 | ARGENX US, INC. | $1.05 | 06/18/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148662 |
| Principal investigator 1 | ARGENX US, INC. | $5.25 | 06/18/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148666 |
| Principal investigator 1 | ARGENX US, INC. | $3.50 | 06/18/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148670 |
| Principal investigator 1 | ARGENX US, INC. | $2.10 | 06/18/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148673 |
| Principal investigator 1 | ARGENX US, INC. | $77.40 | 06/18/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148677 |
| Principal investigator 1 | ARGENX US, INC. | $155.25 | 06/18/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148681 |
| Principal investigator 1 | ARGENX US, INC. | $21.35 | 06/18/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148686 |
| Principal investigator 1 | ARGENX US, INC. | $64.05 | 06/18/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148690 |
| Principal investigator 1 | ARGENX US, INC. | $26.50 | 06/18/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148695 |
| Principal investigator 1 | ARGENX US, INC. | $382.00 | 06/18/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148699 |
| Principal investigator 1 | ARGENX US, INC. | $35.80 | 06/18/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148702 |
| Principal investigator 1 | ARGENX US, INC. | $85.40 | 06/18/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148706 |
| Principal investigator 1 | AstraZeneca UK Limited | $8,592.50 | 06/16/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | A Multicenter Randomized Double-blind Placebo-controlled Phase 3 Study Evaluating the Efficacy and Safety of Subcutaneous Anifrolumab in Adult Patients with Systemic Lupus Erythematosus | No dispute reported | 06/30/2026 | 1185542928 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $5,500.00 | 06/13/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | INSPIRE LTE study | No dispute reported | 06/30/2026 | 1246431106 |
| Principal investigator 1 | Janssen Research & Development, LLC | $21,100.00 | 06/09/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA I NC | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? | No dispute reported | 06/30/2026 | 1175394154 |
| Principal investigator 1 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $23,250.00 | 06/04/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF SIBEPRENLIMAB ADMINISTERED SUBCUTANEOUSLY IN SUBJECTS WITH ACTIVE PRIMARY SJGRENS SYNDROME (PSS) | No dispute reported | 06/30/2026 | 1225335917 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $10,000.00 | 06/04/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223280688 |
| Principal investigator 1 | ABBVIE INC. | $2,462.50 | 06/03/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202488601 |
| Principal investigator 1 | Janssen Research & Development, LLC | $250.00 | 06/02/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA I NC | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | No dispute reported | 06/30/2026 | 1175394239 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,000.00 | 06/02/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA I NC | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175394302 |
| Principal investigator 1 | Janssen Research & Development, LLC | $800.00 | 05/23/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA I NC | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | No dispute reported | 06/30/2026 | 1175394178 |
| Principal investigator 1 | ARGENX US, INC. | $1,824.95 | 05/19/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148516 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,700.00 | 05/15/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA I NC | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175394142 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,000.00 | 05/09/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223279338 |
| Principal investigator 1 | ABBVIE INC. | $2,500.00 | 05/08/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate | No dispute reported | 06/30/2026 | 1202484331 |
| Principal investigator 1 | ABBVIE INC. | $3,084.90 | 05/06/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate | No dispute reported | 06/30/2026 | 1202481445 |
| Principal investigator 1 | ABBVIE INC. | $4,487.50 | 05/06/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202481513 |
| Principal investigator 1 | ABBVIE INC. | $2,327.50 | 05/06/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202481515 |
| Principal investigator 1 | ARGENX US, INC. | $3,975.60 | 04/25/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148503 |
| Principal investigator 1 | ARGENX US, INC. | $5,817.60 | 04/25/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148507 |
| Principal investigator 1 | ARGENX US, INC. | $726.00 | 04/25/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148510 |
| Principal investigator 1 | Janssen Research & Development, LLC | $13,550.00 | 04/17/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA I NC | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175394252 |
| Principal investigator 1 | Amgen Inc. | $34,527.17 | 04/16/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjgren's Syndrome (SS) | No dispute reported | 06/30/2026 | 1246640337 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $6,070.00 | 04/16/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223278096 |
| Principal investigator 1 | IDORSIA PHARMACEUTICALS US INC | $460.00 | 04/14/2025 | Non-covered Recipient Entity Advarra, Inc. | A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy | No dispute reported | 06/30/2026 | 1243527493 |
| Principal investigator 1 | IDORSIA PHARMACEUTICALS US INC | $1,345.00 | 04/14/2025 | Non-covered Recipient Entity Advarra, Inc. | A Phase 3, multicenter, open-label, single-arm, extension study to evaluate the long-term safety and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy | No dispute reported | 06/30/2026 | 1243527498 |
| Principal investigator 1 | UCB SA | $48,510.00 | 04/11/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. | No dispute reported | 06/30/2026 | 1246659470 |
| Principal investigator 1 | ABBVIE INC. | $5,000.00 | 04/10/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202475919 |
| Principal investigator 1 | Amgen Inc. | $85,858.27 | 04/09/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity | No dispute reported | 06/30/2026 | 1246640349 |
| Principal investigator 1 | ARGENX US, INC. | $1,200.00 | 04/04/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148513 |
| Principal investigator 1 | ABBVIE INC. | $10,662.50 | 04/03/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202469588 |
| Principal investigator 1 | ABBVIE INC. | $2,392.50 | 04/03/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202471860 |
| Principal investigator 1 | ABBVIE INC. | $5,030.80 | 04/01/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate | No dispute reported | 06/30/2026 | 1202467882 |
| Principal investigator 1 | Janssen Research & Development, LLC | $14,500.00 | 03/31/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA I NC | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? | No dispute reported | 06/30/2026 | 1175394195 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,450.00 | 03/31/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA I NC | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | No dispute reported | 06/30/2026 | 1175394285 |
| Principal investigator 1 | ARGENX US, INC. | $2,500.00 | 03/24/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148824 |
| Principal investigator 1 | ARGENX US, INC. | $2,000.00 | 03/24/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148828 |
| Principal investigator 1 | ARGENX US, INC. | $10,000.00 | 03/24/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148838 |
| Principal investigator 1 | Janssen Research & Development, LLC | $14,500.00 | 03/24/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA I NC | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175394159 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $3,500.00 | 03/21/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | INSPIRE LTE study | No dispute reported | 06/30/2026 | 1246431104 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $10,000.00 | 03/19/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223276853 |
| Principal investigator 1 | Amgen Inc. | $3,598.14 | 03/17/2025 | Non-covered Recipient Entity ARIZONA ARTHRITIS AND RHEUMATOLOGY ASSOCIATES - GLENDALE - 5681 W BEVERLY LN | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity | No dispute reported | 06/30/2026 | 1246639215 |
| Principal investigator 1 | Amgen Inc. | $17,541.90 | 03/10/2025 | Non-covered Recipient Entity CLINICAL RESEARCH WEST FLORIDA INC | A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjgren's Syndrome (SS) | No dispute reported | 06/30/2026 | 1246640363 |
| Principal investigator 1 | ABBVIE INC. | $6,547.50 | 03/07/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202459381 |
| Principal investigator 1 | ABBVIE INC. | $5,303.35 | 03/06/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | M14-465 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate | No dispute reported | 06/30/2026 | 1202456571 |
| Principal investigator 1 | ABBVIE INC. | $100.00 | 03/06/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202458387 |
| Principal investigator 1 | Amgen Inc. | $45,011.75 | 03/03/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC - CLEARWATER | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgrens Syndrome With Moderate-to-Severe Systemic Disease Activity | No dispute reported | 06/30/2026 | 1246640329 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $3,013.87 | 03/03/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | INSPIRE LTE study | No dispute reported | 06/30/2026 | 1246431102 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,280.00 | 02/14/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA I NC | A Phase 2a Multicenter, Randomized, Double Blind, Parallel, Proof of concept Study Evaluating the Efficacy and Safety of Nipocalimab and Certolizumab Combination Therapy in Participants with Active Rheumatoid Arthritis despite Prior Treatment with Advanc | No dispute reported | 06/30/2026 | 1175394216 |
| Principal investigator 1 | ABBVIE INC. | $3,171.25 | 02/05/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202444533 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $17,059.00 | 02/04/2025 | Non-covered Recipient Entity Clinical Research Of West Florida | A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) | No dispute reported | 06/30/2026 | 1235998010 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $453,013.76 | 01/30/2025 | Non-covered Recipient Entity Clinical Research Of West Florida | A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus | No dispute reported | 06/30/2026 | 1235998014 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $11,173.05 | 01/27/2025 | Non-covered Recipient Entity Clinical Research Of West Florida | A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus | No dispute reported | 06/30/2026 | 1235998012 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,100.00 | 01/27/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA I NC | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | No dispute reported | 06/30/2026 | 1175394308 |
| Principal investigator 1 | Amgen Inc. | $28,236.65 | 01/22/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC - CLEARWATER | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants with Sjgrens Syndrome With Moderate-to-Severe Symptom State | No dispute reported | 06/30/2026 | 1246640327 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $119,825.00 | 01/16/2025 | Non-covered Recipient Entity Clinical Research Of West Florida | A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjgren's Syndrome (POETYK SjS-1) | No dispute reported | 06/30/2026 | 1235998020 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $52,904.50 | 01/13/2025 | Non-covered Recipient Entity Clinical Research Of West Florida | A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Nave to Biologic Disease-modifying Anti-rheumatic Drugs | No dispute reported | 06/30/2026 | 1235998016 |
| Principal investigator 1 | ARGENX US, INC. | $1,500.00 | 01/10/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148832 |
| Principal investigator 1 | ARGENX US, INC. | $1,248.00 | 01/10/2025 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome | No dispute reported | 06/30/2026 | 1237148835 |
| Principal investigator 1 | ABBVIE INC. | $4,965.35 | 01/02/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | M14-465 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate | No dispute reported | 06/30/2026 | 1202433477 |
| Principal investigator 1 | ABBVIE INC. | $2,867.50 | 01/02/2025 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202434193 |